Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASTER trial of abelacimab versus apixaban for cancer-associated venous thromboembolism
NL-OMON60918Phase 3Completed
- Sponsor
- Anthos Therapeutics
- Start
- Dec 2022
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in venous thromboembolism (VTE) comparing Abelacimab with Apixaban (2 arms). Primary endpoint: Time to first event of centrally adjudicated VTE recurrence through 6 months. Started Dec 2022; status: completed.
02
Drugs
abelacimabapixaban
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on NL-OMON60918.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60918.